Who Paid My Doc Search
Menu
Organisation paid for research Program year 2025 Source: CMS Open Payments

Sec Clinical Research LLC

Neither a doctor nor a teaching hospital

Research payments

$6,205,078

961 payments

Through program year 2025, Sec Clinical Research LLC is reported as receiving $6,205,078 in research payments, across 961 payments.

By program year

7 rows
Year Kind Amount Payments
2025 Research $1,958,244 308
2024 Research $1,212,093 213
2023 Research $1,476,867 206
2022 Research $874,125 172
2021 Research $172,173 21
2020 Research $158,331 15
2019 Research $353,244 26

Breakdown

Who paid Research payments · program years 2019–2025
  1. Moderna TX, Inc. $1,935,112 269 payments
  2. Genentech, Inc. $1,174,733 266 payments
  3. AstraZeneca Pharmaceuticals LP $1,136,660 37 payments
  4. Sun Pharmaceutical Industries Inc. $308,816 214 payments
  5. Eli Lilly and Company $284,356 3 payments
  6. Boehringer Ingelheim Pharmaceuticals, Inc. $276,152 18 payments
  7. Hoffmann-La Roche Limited $249,867 32 payments
  8. Novartis Pharmaceuticals Corporation $214,375 3 payments
  9. Verona Pharma, Inc. $148,285 11 payments
  10. GlaxoSmithKline, LLC. $134,771 26 payments
Studies the money was for Research payments · program years 2019–2025
  1. A Phase 3, Randomized, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age $1,280,233 84 payments
  2. PH Iib of Astegolimab in COPD $894,367 206 payments
  3. A Phase IIb Randomised, Double-blind, Placebocontrolled Study to Evaluate the Efficacy, Safety and Tolerability of Coadministration of AZD9550 and AZD6234 in Participants Living With Obesity or Overweight with Co-morbidity (ASCEND) $475,823 1 payment
  4. Ph III OLE of Astegolimab in COPD $413,017 84 payments
  5. A Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age $302,799 25 payments
  6. A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Effect of Lepodisiran on the Reduction of Major Adverse Cardiovascular Events in Adults With Elevated Lipoprotein(A) Who Have Established Atherosclerotic Cardiovascular Disease Or Are at Risk for A First Cardiovascular Event - Acclaim-Lp(A) $284,356 3 payments
  7. Efficacy and Safety of Tildrakizumab Compared to Placebo in Subjects With Active Psoriatic Arthritis I (INSPIRE 1) $226,269 164 payments
  8. A Study of mRNA-1345 Vaccine Targeting Respiratory Syncytial Virus in Pregnant Women and in Infants Born to Vaccinated Mothers $177,941 116 payments
  9. A Randomized, Double-blind, Placebo-controlled, Parallel Group, Multicenter, Phase 2a Study to Explore the Efficacy and Safety of Tezepelumab in Patients with Moderate to Very Severe Chronic Obstructive Pulmonary Disease (COPD) (COURSE) $158,527 8 payments
  10. A randomised, double-blind, placebo-controlled, dose-finding study evaluating efficacy, safety, and tolerability of different oral doses of BI 1819479 over at least 24 weeks in patients with idiopathic pulmonary fibrosis (IPF) $156,355 14 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record